login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

CONNECT II clinical trial completes enrolment


Wednesday, 13 Jun 2012 09:43
Ocelot
Ocelot

Avinger has announced that it has successfully completed enrolment in its CONNECT II global clinical trial. A study focused on treatment of peripheral artery disease. CONNECT II is a prospective, multicentre, non-randomised global clinical study that evaluated 100 peripheral artery disease patients with femoropopliteal chronic total occlusion lesions at 15 hospital and clinic sites, including two in the European Union.


As part of the trial, an independent group of physicians are reviewing the angiographic results to determine Ocelot’s safety and efficacy. According to Avinger (manufacturer of this device), it is the first-ever interventional chronic total occlusion (CTO) crossing catheter to use real-time intravascular imaging technology called optical coherence tomography, or OCT. It allows physicians to cross, see and navigate inside totally blocked arteries in the legs of patients suffering from peripheral artery disease.

“We are pleased to reach this significant milestone ahead of schedule and already see promising preliminary data collected,” said John B Simpson, CEO and founder, Avinger. “We appreciate the patient participation and dedicated efforts of our employees, physician investigators and their research staff. Together, we are now one step closer to bringing the Ocelot technology to patients who need it most.”


The company will present CONNECT II aggregate results at the VIVA conference (Las Vegas, USA, 9–12 October 2012), file a 510K with the FDA later this summer, and expects to receive 510K clearance in late 2012. In order to ensure Ocelot is available for use at US CONNECT II sites during the 510K review period, Avinger has also requested FDA approval of an additional 125 patients to be enrolled and treated in a continued access cohort.


“I believe the results from this trial will have a major impact on how physicians treat patients with severe peripheral artery disease. We are pleased that a request for continued access has been submitted. It means the Heart Hospital may be able to continue treating patients with Ocelot in order to quickly improve their mobility and return to a healthier quality of life,” said Matthew Selmon, Heart Hospital Austin, Texas and co-principal investigator for the trial.


“This is the first-ever interventional device that allows us to drill through the totally blocked arteries in the legs while using an integrated camera to see it from the inside,” said Arne Schwindt, St Franziskus Hospital, Muenster, Germany and co-principal investigator in the trial. “This is a major advance for patients suffering from peripheral artery disease, and holds the potential to postpone or entirely avoid surgical bypasses and amputations.”


Ocelot received CE mark in 2011.




Add New Comment

Most popular


Philips and Academic Medical Center aim to improve care for diabetic patients with severe foot complications
Thursday, 28 May 2015
The European study in which Philips and AMC are collaborating will start in the summer of 2015 with final results expected in 2017. Philips and Academic Medical Center aim to improve care for diabetic patients with severe foot complications

FDA grants premarket approval for Enroute transcarotid stent system
Tuesday, 19 May 2015
The Enroute transcarotid stent (Silk Road Medical) is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe ... FDA grants premarket approval for Enroute transcarotid stent system

Companies announce new round of renal denervation randomised trials
Monday, 08 Jun 2015
Medtronic has announced the initiation of the SPYRAL HTN clinical trial programme studying renal denervation in uncontrolled hypertension, and Boston Scientific has announced the initiation of the RED... Companies announce new round of renal denervation randomised trials

Features


Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature
Wednesday, 10 Jun 2015
The Aneurysm Coiling Efficiency registry offers an opportunity to study the demographics and long-term outcomes of a cohort of patients with embolization of the peripheral vasculature using Ruby ... Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature

Interventional radiology solutions for hydatic disease
Wednesday, 10 Jun 2015
Hydatid disease (cystic Echinococcus) caused by Echinococcus granulosus is an endemic disease and a significant public health problem in many parts of the world. Interventional radiology solutions for hydatic disease

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focussing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions